When a range of hematological cancer cell lines, including ALL, MM, and DLBCL types, were treated with AZD5153, a novel BRD4 inhibitor, all demonstrated considerable reduction in CD180 mRNA levels (Yeh et al. 2017). This evidence concerns the gene BRD4 and Miyoshi myopathy.